Key Points
- CareDx CEO John Walter Hanna, Jr. sold 10,156 shares on Jan. 15 at an average price of $21.05 for proceeds of $213,783.80, reducing his stake by 1.62% to 616,885 shares; the sale was disclosed in an SEC Form 4 filing.
- CareDx posted a quarterly beat, reporting $0.28 EPS versus $0.13 expected and $100.06M in revenue (up 20.7% YoY), with a 19.65% net margin and 20.15% return on equity.
- Market sentiment is mixed: CDNA trades near $20.20 with a $1.04B market cap, and analysts have a consensus "Hold" rating with an average target of $26.67.
CareDx, Inc. (NASDAQ:CDNA - Get Free Report) CEO John Walter Hanna, Jr. sold 10,156 shares of the firm's stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $21.05, for a total value of $213,783.80. Following the transaction, the chief executive officer owned 616,885 shares of the company's stock, valued at approximately $12,985,429.25. This represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
CareDx Trading Up 0.9%
CDNA stock opened at $20.20 on Wednesday. The business's fifty day moving average price is $18.64 and its 200 day moving average price is $15.84. CareDx, Inc. has a 12-month low of $10.96 and a 12-month high of $25.55. The company has a market capitalization of $1.04 billion, a PE ratio of 16.97 and a beta of 2.49.
CareDx (NASDAQ:CDNA - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.15. The company had revenue of $100.06 million during the quarter, compared to analysts' expectations of $95.25 million. CareDx had a return on equity of 20.15% and a net margin of 19.65%.CareDx's revenue for the quarter was up 20.7% on a year-over-year basis. During the same period last year, the business posted ($0.14) EPS. Research analysts predict that CareDx, Inc. will post -0.9 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of CareDx from a "hold" rating to a "buy" rating in a research note on Sunday, December 21st. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of CareDx in a research report on Monday, December 29th. Zacks Research upgraded CareDx from a "strong sell" rating to a "hold" rating in a research note on Tuesday, November 18th. Craig Hallum cut CareDx from a "buy" rating to a "hold" rating and set a $26.00 target price for the company. in a research note on Tuesday, January 6th. Finally, BTIG Research upped their price target on CareDx from $22.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, November 6th. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $26.67.
Read Our Latest Research Report on CareDx
Institutional Trading of CareDx
Hedge funds and other institutional investors have recently bought and sold shares of the business. MCF Advisors LLC boosted its position in shares of CareDx by 292.9% during the 2nd quarter. MCF Advisors LLC now owns 1,336 shares of the company's stock worth $26,000 after acquiring an additional 996 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in CareDx in the third quarter valued at approximately $31,000. Allworth Financial LP purchased a new position in CareDx in the second quarter valued at approximately $40,000. State of Alaska Department of Revenue acquired a new stake in CareDx during the third quarter worth approximately $43,000. Finally, Quantbot Technologies LP purchased a new stake in shares of CareDx during the 3rd quarter worth approximately $89,000.
CareDx Company Profile
(
Get Free Report)
CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
